New PET tracer aims to spot Parkinson's protein in the brain

NCT ID NCT06891703

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive tracer called [18F]ACI-15916, designed to detect clumps of α-synuclein protein in the brain using PET scans. These protein deposits are linked to Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. The trial will include 46 people—both healthy volunteers and those with suspected α-synuclein-related conditions—to check if the tracer is safe and can reliably show differences in protein buildup between groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[18F]ACI-15916 (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a reliable brain scan to diagnose diseases like Parkinson's and Lewy body dementia earlier and more accurately.
What could go wrong
This is a very early Phase 1 study with only 46 participants. The tracer may not bind well to α-synuclein or may cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES (DLB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Karolinska Institutet

    RECRUITING

    Solna, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.